diagnosme

Detailed mobile health tracking & early detection of disease while you workout.


Sign Up for Our Mailing List:
And Follow Us On

Coming Soon to iOS, Android, and Windows Phone.

Early Warnings of Disease.

Early-detection devices for chronic diseases play an integral role in lowering healthcare costs and improving patient survival rates. DiagnosMe is a new venture in which a team of undergraduates has built a color-based test for a specific protein found in sweat. The protein is correlated with chronic diseases and is a marker of immune system activity. It is found at very low levels in healthy patients, and jumps ten-fold in patients with chronic diseases.

The current state of the art testing for the protein is lab-based and requires expensive shipping and analysis procedures. DiagnosMe bridges the gap between user and results by bringing the test right into the user's home. The purpose of the device is to detect illnesses early in their development by enabling users to monitor levels of this protein in their sweat over time using a sweat collection device and a smartphone application. If a user experiences a sustained elevated level of this protein for many weeks, he or she is advised by the smartphone application to see a physician for proper symptomatic diagnosis and monitoring. The team's ultimate vision for DiagnosMe is to create biosensors for many specific chronic diseases associated with this protein family, and to provide convenient analysis for high-risk or in-remission patients. In addition, the team is working to create a device that will give users an even broader view of their health by incorporating components such as the user's cellular device, a heart rate monitor, thermometer, pedometer, and blood pressure measurement device.

The device thus far has been tested on one of these proteins and is both accurate and precise with respect to the state of the art lab-based test. In addition, the device was able to detect changes in the immune systems of individuals diagnosed with the flu. The future of telemedicine is focused on integrating the patient with modern diagnostic techniques and their smartphones. DiagnosMe is part of the telemedicine movement because it allows users to utilize innovative new diagnostic procedures along with their smartphones in order to monitor their health. DiagnosMe has been registered as an LLC, and the technology is patent-pending. The device has been built and tested as an immune system protein monitoring and diagnostic system that will help users catch chronic diseases earlier, with the hope of improving the prevention and treatment of disease.


Our Team

Kiah Williams, Chief Executive Officer
Kiah Williams is the Chief Executive Officer of DiagnosMe and is studying Human Biology and Hispanic Studies at Dartmouth College. She plans to enter into an M.D./Ph.D. program after graduating and hopes to become a cardiac surgeon. Kiah is involved in multiple medical research projects at Dartmouth and in her home state of Colorado. Kiah has worked in retail, sales, management, marketing, teaching, and research. She was a top-performing branch founder and manager for Revolution Prep in 2012, and is a Sophomore Science Scholar at Dartmouth for her research on how cardiopulmonary bypass causes brain injury. This research includes the first use of a mouse model for cardiopulmonary bypass.

Rob Lauzen, Chief Operating Officer
Rob is the Chief Operating Officer of DiagnosMe and is a sophomore at Dartmouth College studying Engineering with a focus in Biology. He is interested in the convergence of cutting-edge biomedical and healthcare technologies and ideas with global capital. Rob has a background in a wide range of industries through internships with Cypress Semiconductor in San Jose, CA, MacLean-Fogg Component Solutions in Krefeld, Germany, and National Financial Partners in New York, NY. Each experience has provided a different perspective and approach to engineering and management. Outside of the classroom, he is a member of the Dartmouth varsity football team.

Katherine Franklin, Chief Scientific Officer
Katherine is the Chief Scientific Officer of DiagnosMe. Katherine is a sophomore at Dartmouth College studying biomedical engineering with the intention of pursuing a PhD after graduation. She has experience in both a multimodal neuroimaging lab and an orthopedics lab. Her work in the brain imaging lab led her to conduct a one year independent research project focusing on traumatic brain injury in soldiers. Her work in the orthopedics lab over the past five years has produced many research abstracts accepted by the Orthopedic Research Society. In addition to classes and research, Katherine has experience working in retail, has volunteered as a tutor to her peers, holds a leadership role as an Undergraduate Advisor, and is a board member of the nonprofit Nepalese Children's Health and Education Foundation.

Riley Ennis, VP Clinical Development
Riley is the Senior Vice President of Clinical Development at DiagnosMe. Riley previously founded a biotechnology startup, Immudicon LLC. He worked for three years on a cancer vaccine technology that teaches the immune cells of the body to recognize and remove tumors. He worked to receive over $10,000 in initial funding to start Immudicon, which is focused on licensing the cancer vaccine platform technology. The vaccine has been recognized by the GE Focus Forward Competition, the Intel International Science Fair, the BioGENEius Challenge, AXA Equitable Achievement Award, National Young Inventors Gallery, and the Virginia Academy of Science. Riley is currently a sophomore at Dartmouth College and wants to double major in economics and biology.

Share Us with Your Friends!

Our Tests

Multiple early stage tests have been done to assess the viability and dependability of the DiagnosMe device.

  • Overview

    The DiagnosMe device consists of a sweat collection device, a biosensor, and an iPhone application. Together, these components give the user an accurate quantification of his or her current immune system activity. In the future, the product will also include components that will give the user even more information about his or her health such as a heart rate monitor, blood pressure measurement device, pedometer and thermometer.

    The current sweat collection device consists of a very small clip that is worn by the user during exercise. Sweat is collected through a sponge-like mechanism and enters the chamber where the biosensor is placed. Multiple users have given this clip a high comfort and design rating. However, we hope to expand on our current model to make the collection device exist in a headband or patch in order to collect sweat more efficiently.

    The function of the biosensor is to conduct the same biomolecule concentration analysis that would be performed in a laboratory setting, but in a much simpler, more elegant form. In the laboratory, the test requires specialized equipment and experience with scientific procedures. With the biosensor, the user simply inserts the test strip into the device described above and the sweat will incubate on the strip during the workout. This produces a colorimetric change that is directly proportional to the concentration of the biomolecule of interest in the sample. We developed this prototype with user convenience in mind, so that no scientific background and minimal extra time would be required for an individual to monitor his or her immune activity. The results of this novel method are also very accurate when compared with the results of the standard laboratory technique.

    The results from the biosensor are analyzed using a smartphone application. Rather than requiring the user to purchase a separate analysis system, DiagnosMe utilizes the convenience of a device that many people already own. The user simply takes an image of the biosensor with the smartphone camera after the test has been conducted and the application then uses image densitometry to analyze the colorimetric change. The application correlates the colorimetric change to an approximate biomarker concentration value. The value can be reported to the user, tracked over time, and even used to provide a recommendation to see a doctor if the levels are elevated for an extended period of time.

  • Sweat Collection Device

    Which clip prototype will collect more sweat? The clip with sponge instead of sweat ramp collected more sweat in the same amount of time.



    Does a new clip prototype with a diagonal sponge consitently collect enough sweat? Yes. About 300 ul of sweat are ideal for the test.



    Is the clip comfortable? What did the users suggest? Nine users were asked to rank the comfort of the device and say whether or not they would use it if it could help them detect disease. All users said they would use the device, and the average comfort rating was 8 out of 10. Users recommended having the device in a headband or a patch to wear under the arm. The location of placement of the device, material of device, and surface area of sponge in contact with skin are being reevaluated in order to optimize sweat collection. These possibilities will be assessed through future tests.

  • Benchmark Testing

    Benchmark testing for the biosensor using the current state of the art included looking at both a standard 96-well ELISA and Luminex-based Flow Cytometry method. Physicians, laboratory scientists, and companies use these methods to analyze bodily fluids for calculating protein levels.


    Can a standard curve be created using a state of the art 96-well ELISA Will this standard curve cover the range of biomolecule concentrations needed? Yes, a standard curve was successfully created using 96-well ELISA that covers the necessary concentration range. This confirms the feasibility of this test as a standard of comparison to our device and the accuracy of the technology to test for biomolecule levels within our range of interest.



    Can a more precise standard curve be created using Luminex-based Flow Cytometry? Yes, but this method is very expensive and produces extremely similar results to the 96-well ELISA standard, so the 96-well ELISA standard is sufficient for the study.

  • Biosensor Testing

    The primary goal of biosensor testing was to determine the practicality of using the biosensor and image densitometry instead of the traditional 96-well ELISA technique. In addition, the accuracy, speed, and precision of the biosensor and how external factors can affect the biomolecule levels were assessed.


    Can a standard curve be built using the new biosensors? Will this curve match the 96-well ELISA standard curve and a theoretical curve? Yes. Standard curves were built from the biosensors three separate times and it was found that the precision of the device between standard curves was variable around 10 pg/ml. The theoretical curve and the state of the art predicted that the sample would read between 10-12 pg/ml, and the biosensor data calculated that level to be around 16.3 pg/ml. Because the device is based on general thresholds with ranges of about 50 pg/ml, this 10 pg/ml discrepancy is irrelevant in terms of disease progression. In addition, users are only provided with doctor recommendations based upon their level if they have been in the unhealthy range for several weeks, and thus this 10 pg/ml variability within individual measurements is negligible over time.



    Will the biosensor maintain precision between separate measurements? Yes. Two biosensors were constructed and tested with the same sweat sample The results of the two biosensors differed by only 2.3 ug/ml.

  • Functionality Testing

    Will the concentration of the target biomolecule be elevated in sick individuals, as predicted? Yes. Two individuals were tested using the biosensor throughout the progression of illness, and both individuals had elevated levels of the target biomolecule when sick. Interestingly, high concentrations of the target biomolecule were observed a day or two prior to the appearance of symptoms. This observation supports the claim that DiagnosMe can recognize the development of illness before symptoms are present.



    How will impurities affect the biosensor readings? The biosensor readings were not affected significantly by the presence of sunscreen, antiperspirant, and lotion in the sweat sample, but the reading was greatly affected by perfume. Users would be advised not to wear perfume while using DiagnosMe.



    How will the volume of sweat being tested affect the accuracy of the biosensor? It was determined that for a volume between 200-250 ul, the accuracy of the biosensor stayed within approximately 1 pg/ml of the actual concentration measured at 300 ul. Furthermore, even when the volume was only between 100-150 ul, the accuracy was still within 4 pg/ml of the actual concentration measured at 300 ul. This data shows that DiagnosMe will still deliver reasonably accurate results if a less than ideal volume of sweat is collected.